News - Page 2 - Psychedelic Alpha

Read more about the article Cautious Optimism, Lingering Questions: Researchers React to Compass’ Phase 3 Psilocybin Results

Cautious Optimism, Lingering Questions: Researchers React to Compass’ Phase 3 Psilocybin Results

Post published:June 25, 2025
Post category:Analysis News Pα+

Read more about the article Compass Pathways’ Psilocybin Clears First Phase 3 Hurdle

Compass Pathways’ Psilocybin Clears First Phase 3 Hurdle

Post published:June 23, 2025
Post category:Analysis News

Read more about the article Australia’s Largest Private Health Insurer Commits $10M to Fund MDMA Therapy for PTSD in First-of-its-Kind Program

Australia’s Largest Private Health Insurer Commits $10M to Fund MDMA Therapy for PTSD in First-of-its-Kind Program

Post published:June 18, 2025
Post category:Analysis News Pα+

Read more about the article Pα+ Psychedelic Bulletin #201: Dispatches from Prague and London; Texas Becomes Leader in Ibogaine Research as Governor Signs $50M Match-Funding Bill; High-Dose LSD Shows Potential in Depression, But Findings Are Fragile

Pα+ Psychedelic Bulletin #201: Dispatches from Prague and London; Texas Becomes Leader in Ibogaine Research as Governor Signs $50M Match-Funding Bill; High-Dose LSD Shows Potential in Depression, But Findings Are Fragile

Post published:June 13, 2025
Post category:Psychedelic Bulletin Pα+

Read more about the article May 2025 Psychedelic Patent Update: Gilgamesh Broadens Moat Around Lead Candidate Following Positive Phase 2a Readout; Lykos Publishes Further Continuation Applications; Reconnect Joins Crowded 5-MeO-DMT Patent Landscape

May 2025 Psychedelic Patent Update: Gilgamesh Broadens Moat Around Lead Candidate Following Positive Phase 2a Readout; Lykos Publishes Further Continuation Applications; Reconnect Joins Crowded 5-MeO-DMT Patent Landscape

Post published:June 12, 2025
Post category:Psychedelic Patent Analysis Pα+

Read more about the article Psychedelic Bulletin #200: Can Czechia Deliver on Psilocybin Access? A Closer Look at ‘atai Beckley’; Q1’25 Psychedelic Lobbying Update; Catching Up with the Class of Bulletin #100

Psychedelic Bulletin #200: Can Czechia Deliver on Psilocybin Access? A Closer Look at ‘atai Beckley’; Q1’25 Psychedelic Lobbying Update; Catching Up with the Class of Bulletin #100

Post published:June 6, 2025
Post category:Psychedelic Bulletin

Read more about the article The Backyard Psychedelic Renaissance: How Bottom-Up Change Is Delivering Psychedelic Access

The Backyard Psychedelic Renaissance: How Bottom-Up Change Is Delivering Psychedelic Access

Post published:June 4, 2025
Post category:Op-ed

Read more about the article Breaking: atai Moves to Acquire Beckley, If Phase 2b 5-MeO-DMT Data Delivers

Breaking: atai Moves to Acquire Beckley, If Phase 2b 5-MeO-DMT Data Delivers

Post published:June 2, 2025
Post category:Analysis News Pα+

Read more about the article Pα+ Psychedelic Bulletin #199: Lykos Takeover Nears Completion; Fewer than 100 Patients Received Psychedelics in Australia During First 18 Months of Access; Ibogaine Bill Clears Texas Legislature Amid THC Crackdown

Pα+ Psychedelic Bulletin #199: Lykos Takeover Nears Completion; Fewer than 100 Patients Received Psychedelics in Australia During First 18 Months of Access; Ibogaine Bill Clears Texas Legislature Amid THC Crackdown

Post published:May 30, 2025
Post category:Psychedelic Bulletin Pα+

Read more about the article Can a State Fast-Track a Psychedelic Breakthrough? Inside Texas’ Plan to Fund Ibogaine Trials

Can a State Fast-Track a Psychedelic Breakthrough? Inside Texas’ Plan to Fund Ibogaine Trials

Post published:May 28, 2025
Post category:Analysis News

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.